{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:05:05Z","timestamp":1780459505830,"version":"3.54.1"},"reference-count":76,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>Objective: To identify FDA-authorized prescription or clinician-directed digital mental health products, including applications and software-enabled devices, for psychiatric treatment or diagnostic support. Methods: FDA Medical Device Databases were searched for records associated with nine product codes relevant to digital mental health. Eligible records were consolidated into distinct product families. Peer-reviewed literature and FDA documentation were reviewed to characterize indications, authorization pathways, and the quality of supporting evidence. Results: Sixteen digital mental health products and software-enabled devices authorized by the FDA met the inclusion criteria. Twelve products supported treatment for substance use disorders, insomnia, attention-deficit\/hyperactivity disorder (ADHD), posttraumatic stress disorder (PTSD)-related conditions, major depressive disorder, generalized anxiety disorder, and postpartum depression. Four products provided diagnostic support for ADHD or autism spectrum disorder. Authorization was granted through either 510(k) clearance or De Novo classification, with considerable variation in the quantity, independence, and clinical relevance of supporting evidence. Conclusions: FDA marketing authorization does not uniformly indicate clinical effectiveness. Because 510(k) clearance, De Novo classification, and premarket approval (PMA) reflect distinct regulatory standards, clinicians should interpret digital mental health products in the context of the specific authorization pathway, product indication, and supporting evidence base.<\/jats:p>","DOI":"10.3390\/brainsci16060576","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:37:26Z","timestamp":1780454246000},"page":"576","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Digital Mental Health: A Narrative Review of FDA-Authorized Products for Psychiatric Treatment and Diagnostic Support"],"prefix":"10.3390","volume":"16","author":[{"given":"Jehad","family":"Albitar","sequence":"first","affiliation":[{"name":"Department of Behavioral Medicine and Psychiatry, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV 26506, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6158-093X","authenticated-orcid":false,"given":"Krista","family":"Ulisse","sequence":"additional","affiliation":[{"name":"Department of Behavioral Medicine and Psychiatry, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV 26506, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0560-8202","authenticated-orcid":false,"given":"Christopher","family":"Feghali","sequence":"additional","affiliation":[{"name":"Department of Behavioral Medicine and Psychiatry, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV 26506, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1709-4782","authenticated-orcid":false,"given":"Dorothy","family":"van Oppen","sequence":"additional","affiliation":[{"name":"Department of Behavioral Medicine and Psychiatry, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV 26506, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Zell","sequence":"additional","affiliation":[{"name":"Department of Behavioral Medicine and Psychiatry, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV 26506, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3131-3419","authenticated-orcid":false,"given":"Daniel","family":"Elswick","sequence":"additional","affiliation":[{"name":"Department of Behavioral Medicine and Psychiatry, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV 26506, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1001\/jamapsychiatry.2017.0303","article-title":"Geographic Access to Specialty Mental Health Care Across High- and Low-Income US Communities","volume":"74","author":"Cummings","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jamapsychiatry.2025.3575","article-title":"Telemental Health, Hybrid, and In-Person Outpatient Mental Health Care in the US","volume":"83","author":"Olfson","year":"2026","journal-title":"JAMA Psychiatry"},{"key":"ref_3","unstructured":"International Medical Device Regulators Forum (2013). Software as a Medical Device (SaMD): Key Definitions, International Medical Device Regulators Forum."},{"key":"ref_4","unstructured":"U.S. Food and Drug Administration (2026, March 05). Software as a Medical Device (SaMD), Available online: https:\/\/www.fda.gov\/medical-devices\/digital-health-center-excellence\/software-medical-device-samd."},{"key":"ref_5","unstructured":"American Psychiatric Association (2023). Digital Mental Health 101: What Clinicians Need to Know When Getting Started, American Psychiatric Association."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s44184-025-00174-2","article-title":"FDA-authorized software as a medical device in mental health: A perspective on evidence, device lineage, and regulatory challenges","volume":"4","author":"Herpertz","year":"2025","journal-title":"npj Ment. Health Res."},{"key":"ref_7","unstructured":"U.S. Food and Drug Administration (2026, May 06). De Novo Classification Request, Available online: https:\/\/www.fda.gov\/medical-devices\/premarket-submissions-selecting-and-preparing-correct-submission\/de-novo-classification-request."},{"key":"ref_8","unstructured":"U.S. Food and Drug Administration (2021). Medical Device De Novo Classification Process, Final Rule."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jama.2021.11171","article-title":"FDA Regulation and Approval of Medical Devices: 1976\u20132020","volume":"326","author":"Darrow","year":"2021","journal-title":"JAMA"},{"key":"ref_10","unstructured":"U.S. Food and Drug Administration (2021). De Novo Classification Request for EaseVRx (DEN210014)."},{"key":"ref_11","unstructured":"U.S. Food and Drug Administration (2002). 510(k) Premarket Notification: RESPeRATE (K020399)."},{"key":"ref_12","unstructured":"U.S. Food and Drug Administration (2017). De Novo Classification Request for reSET (DEN160018)."},{"key":"ref_13","unstructured":"U.S. Food and Drug Administration (2018). 510(k) Premarket Notification for reSET-O (K173681)."},{"key":"ref_14","unstructured":"U.S. Food and Drug Administration (2024). 510(k) Premarket Notification for Rejoyn (K231209)."},{"key":"ref_15","unstructured":"U.S. Food and Drug Administration (2024). 510(k) Premarket Notification for DaylightRx (K233872)."},{"key":"ref_16","unstructured":"U.S. Food and Drug Administration (2024). 510(k) Premarket Notification for MamaLift Plus (K223515)."},{"key":"ref_17","unstructured":"U.S. Food and Drug Administration (2020). 510(k) Premarket Notification for Somryst (K191716)."},{"key":"ref_18","unstructured":"U.S. Food and Drug Administration (2024). 510(k) Premarket Notification for SleepioRx (K233577)."},{"key":"ref_19","unstructured":"U.S. Food and Drug Administration (2020). De Novo Classification Request for EndeavorRx (DEN200026)."},{"key":"ref_20","unstructured":"U.S. Food and Drug Administration (2023). 510(k) Premarket Notification K231337: EndeavorRx."},{"key":"ref_21","unstructured":"U.S. Food and Drug Administration (2025). 510(k) Premarket Notification: Prismira (K243729)."},{"key":"ref_22","unstructured":"U.S. Food and Drug Administration (2013). 510(k) Premarket Notification for Canary Breathing System (Freespira)\u2014Panic Disorder (K131586)."},{"key":"ref_23","unstructured":"U.S. Food and Drug Administration (2018). 510(k) Premarket Notification for Freespira\u2014Post-Traumatic Stress Disorder (K180173)."},{"key":"ref_24","unstructured":"U.S. Food and Drug Administration (2020). De Novo Classification Request for NightWare (DEN200033)."},{"key":"ref_25","unstructured":"U.S. Food and Drug Administration (2023). 510(k) Premarket Notification: Prism (K222101)."},{"key":"ref_26","unstructured":"U.S. Food and Drug Administration (2021). De Novo Classification Request for CanvasDx (DEN200069)."},{"key":"ref_27","unstructured":"U.S. Food and Drug Administration (2025). 510(k) Premarket Notification K243558: Canvas Dx."},{"key":"ref_28","unstructured":"U.S. Food and Drug Administration (2022). 510(k) Premarket Notification K213882: EarliPoint System."},{"key":"ref_29","unstructured":"U.S. Food and Drug Administration (2023). 510(k) Premarket Notification for EarliPoint Evaluation System (K230337)."},{"key":"ref_30","unstructured":"U.S. Food and Drug Administration (2025). 510(k) Premarket Notification K243891: EarliPoint System."},{"key":"ref_31","unstructured":"U.S. Food and Drug Administration (2026). 510(k) Premarket Notification K253442: EarliPoint Assessment."},{"key":"ref_32","unstructured":"U.S. Food and Drug Administration (2004). 510(k) Premarket Notification K040894: QbTest."},{"key":"ref_33","unstructured":"U.S. Food and Drug Administration (2012). 510(k) Premarket Notification for QbTest (K122149)."},{"key":"ref_34","unstructured":"U.S. Food and Drug Administration (2014). 510(k) Premarket Notification for QbTest (K133382)."},{"key":"ref_35","unstructured":"U.S. Food and Drug Administration (2016). 510(k) Premarket Notification K143468: QbCheck."},{"key":"ref_36","unstructured":"U.S. Food and Drug Administration (2017). 510(k) Premarket Notification: Test of Variables of Attention (T.O.V.A.) Version 9.0 (K170082)."},{"key":"ref_37","unstructured":"U.S. Food and Drug Administration (2018). 510(k) Premarket Notification for TOVA 9 (K173915)."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ajad.13346","article-title":"Evaluation of real-world outcomes associated with use of a prescription digital therapeutic to treat substance use disorders","volume":"32","author":"Xiong","year":"2023","journal-title":"Am. J. Addict."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1007\/s12325-022-02215-0","article-title":"Real-World Reductions in Healthcare Resource Utilization over 6 Months in Patients with Substance Use Disorders Treated with a Prescription Digital Therapeutic","volume":"39","author":"Shah","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_40","unstructured":"Pear Therapeutics Inc. (2023). Pear Therapeutics Files for Chapter 11 and Will Seek to Sell Assets Through Sales Process."},{"key":"ref_41","unstructured":"Taylor, P. (Pharmaphorum, 2024). PursueCare Brings Pear addiction DTx Apps Back to life, Pharmaphorum."},{"key":"ref_42","unstructured":"Aguilar, M. (STAT News, 2024). Digital Therapeutics Pioneer Pear\u2019s Treatments Get a Second Life, a Year After Bankruptcy, STAT News."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/03007995.2020.1846023","article-title":"Real-world evidence for a prescription digital therapeutic to treat opioid use disorder","volume":"37","author":"Maricich","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1007\/s12325-022-02217-y","article-title":"Reduced Healthcare Resource Utilization in Patients with Opioid Use Disorder in the 12 Months After Initiation of a Prescription Digital Therapeutic","volume":"39","author":"Velez","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1080\/03007995.2022.2108616","article-title":"Network meta-analysis comparing the effectiveness of a prescription digital therapeutic for chronic insomnia to medications and face-to-face cognitive behavioral therapy in adults","volume":"38","author":"Forma","year":"2022","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/17434440.2020.1852929","article-title":"Profile of Somryst Prescription Digital Therapeutic for Chronic Insomnia: Overview of Safety and Efficacy","volume":"17","author":"Morin","year":"2020","journal-title":"Expert Rev. Med. Devices"},{"key":"ref_47","unstructured":"(2023). Nox Health Closes Acquisition of Somryst, the Only FDA-Cleared Digital Insomnia Treatment, From Pear Therapeutics, Nox Health."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e84323","DOI":"10.2196\/84323","article-title":"The Effectiveness of Digital Cognitive Behavioral Therapy to Treat Insomnia Disorder in US Adults: Nationwide Decentralized Randomized Controlled Trial","volume":"12","author":"Prather","year":"2025","journal-title":"JMIR Ment. Health"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"769","DOI":"10.5665\/sleep.1872","article-title":"A Randomized, Placebo-Controlled Trial of Online Cognitive Behavioral Therapy for Chronic Insomnia Disorder Delivered via an Automated Media-Rich Web Application","volume":"35","author":"Espie","year":"2012","journal-title":"Sleep"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00787-023-02174-z","article-title":"Effects of game-based digital therapeutics on attention deficit hyperactivity disorder in children and adolescents as assessed by parents or teachers: A systematic review and meta-analysis","volume":"33","author":"Oh","year":"2024","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Gabarron, E., Denecke, K., and Lopez-Campos, G. (2025). Evaluating the evidence: A systematic review of reviews of the effectiveness and safety of digital interventions for ADHD. BMC Psychiatry, 25.","DOI":"10.1186\/s12888-025-06825-0"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/da.23079","article-title":"Efficacy of digital cognitive behavioral therapy for moderate-to-severe symptoms of generalized anxiety disorder: A randomized controlled trial","volume":"37","author":"Carl","year":"2020","journal-title":"Depress. Anxiety"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"119409","DOI":"10.1016\/j.jad.2025.119409","article-title":"A digital therapeutic (CT-152) as adjunct to antidepressant medication: A phase 3 randomized controlled trial (the Mirai study)","volume":"388","author":"Rothman","year":"2025","journal-title":"J. Affect. Disord."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2470547019877880","DOI":"10.1177\/2470547019877880","article-title":"Initial Evidence for Brain Plasticity Following a Digital Therapeutic Intervention for Depression","volume":"3","author":"Hoch","year":"2019","journal-title":"Chronic Stress"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e69050","DOI":"10.2196\/69050","article-title":"Evaluating the Efficacy of MamaLift Plus Digital Therapeutic Mobile App for Postpartum Depression (SuMMER): Randomized, Placebo-Controlled Pivotal Trial","volume":"27","author":"Dixit","year":"2025","journal-title":"J. Med. Internet Res."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Cuyler, R.N., Katdare, R., Thomas, S., and Telch, M.J. (2022). Real-world outcomes of an innovative digital therapeutic for treatment of panic disorder and PTSD: A 1500 patient effectiveness study. Front. Digit. Health, 4.","DOI":"10.3389\/fdgth.2022.976001"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"361","DOI":"10.5664\/jcsm.10338","article-title":"A randomized sham-controlled clinical trial of a novel wearable intervention for trauma-related nightmares in military veterans","volume":"19","author":"Davenport","year":"2023","journal-title":"J. Clin. Sleep Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"115711","DOI":"10.1016\/j.psychres.2023.115711","article-title":"Amygdala-derived-EEG-fMRI-pattern neurofeedback for the treatment of chronic post-traumatic stress disorder. A prospective, multicenter, multinational study evaluating clinical efficacy","volume":"333","author":"Fruchter","year":"2024","journal-title":"Psychiatry Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41746-022-00598-6","article-title":"Evaluation of an artificial intelligence-based medical device for diagnosis of autism spectrum disorder","volume":"5","author":"Megerian","year":"2022","journal-title":"npj Digit. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"29503","DOI":"10.1038\/s41598-025-15575-8","article-title":"An analysis of the real world performance of an artificial intelligence based autism diagnostic","volume":"15","author":"Salomon","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/jama.2023.13295","article-title":"Eye-Tracking\u2013Based Measurement of Social Visual Engagement Compared with Expert Clinical Diagnosis of Autism","volume":"330","author":"Jones","year":"2023","journal-title":"JAMA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jaac.2023.03.011","article-title":"Systematic Review and Meta-Analysis: Clinical Utility of Continuous Performance Tests for the Identification of Attention-Deficit\/Hyperactivity Disorder","volume":"63","author":"Arrondo","year":"2024","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/DRDR7171","article-title":"Clinical and cost-effectiveness of technologies for the assessment of attention deficit hyperactivity disorder: A systematic review and economic model","volume":"29","author":"Tomlinson","year":"2025","journal-title":"Health Technol. Assess."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/jcpp.13901","article-title":"Practitioner Review: Clinical utility of the QbTest for the assessment and diagnosis of attention-deficit\/hyperactivity disorder\u2014A systematic review and meta-analysis","volume":"65","author":"Bellato","year":"2024","journal-title":"J. Child Psychol. Psychiatry"},{"key":"ref_65","unstructured":"U.S. Food and Drug Administration (2014). The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]\u2014Guidance for Industry and Food and Drug Administration Staff."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41746-022-00668-9","article-title":"Regulatory considerations to keep pace with innovation in digital health products","volume":"5","author":"Torous","year":"2022","journal-title":"npj Digit. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e20192528","DOI":"10.1542\/peds.2019-2528","article-title":"Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit\/Hyperactivity Disorder in Children and Adolescents","volume":"144","author":"Wolraich","year":"2019","journal-title":"Pediatrics"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41746-023-00760-8","article-title":"Digital mental health care: Five lessons from Act 1 and a preview of Acts 2\u20135","volume":"6","author":"Insel","year":"2023","journal-title":"npj Digit. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41746-020-00370-8","article-title":"Characteristics and challenges of the clinical pipeline of digital therapeutics","volume":"3","author":"Patel","year":"2020","journal-title":"npj Digit. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamapsychiatry.2025.3439","article-title":"Uptake, Adherence, and Attrition in Clinical Trials of Depression and Anxiety Apps","volume":"83","author":"Liu","year":"2026","journal-title":"JAMA Psychiatry"},{"key":"ref_71","unstructured":"Centers for Medicare & Medicaid Services (2024). Calendar Year 2025 Medicare Physician Fee Schedule Final Rule [CMS-1807-F], Centers for Medicare & Medicaid Services."},{"key":"ref_72","unstructured":"Stringer, H. (2025). New Reimbursement Pathways Have Opened Doors for Using Digital Therapeutics, APA Services Practice Organization."},{"key":"ref_73","unstructured":"Cigna Health and Life Insurance Company, The Cigna Group (2025). Prescription Digital Therapeutics\u2014Medical Coverage Policy, Cigna Healthcare."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e82677","DOI":"10.2196\/82677","article-title":"Efficacy, User Engagement, and Acceptability of CBT-oriented Psychological Chatbots for Adults with Depressive and\/or Anxiety Symptoms: Systematic Review and Meta-analysis of Randomized Controlled Trials","volume":"28","author":"Gong","year":"2026","journal-title":"J. Med. Internet Res."},{"key":"ref_75","unstructured":"Parliament, E., and Council of the European Union (2026, May 25). Regulation (EU) 2017\/745 of the European Parliament and of the Council of 5 April 2017 on Medical Devices, Amending Directive 2001\/83\/EC, Regulation (EC) No 178\/2002 and Regulation (EC) No 1223\/2009 and Repealing Council Directives 90\/385\/EEC and 93\/42\/EEC, Available online: https:\/\/eur-lex.europa.eu\/eli\/reg\/2017\/745\/oj."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41746-025-02191-z","article-title":"Policy and reimbursement strategies to improve patient access to prescription digital therapeutics","volume":"8","author":"Reilly","year":"2025","journal-title":"npj Digit. Med."}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/16\/6\/576\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:37:10Z","timestamp":1780457830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/16\/6\/576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":76,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["brainsci16060576"],"URL":"https:\/\/doi.org\/10.3390\/brainsci16060576","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]}}}